Pros and Cons of Denosumab Treatment for Osteoporosis and Implication for RANKL Aptamer Therapy

Keyphrases

• Osteoporosis 100%
• Aptamer 100%
• Denosumab 100%
• Osteoclast 40%
• RANKL Inhibitors 40%
• High Stability 20%
• High Affinity 20%
• SsODN 20%
• Drug Target 20%
• Therapeutic Agents 20%
• Adverse Events 20%
• Target Molecule 20%
• Bone Resorption 20%
• Receptor Activator of nuclear factor-B Ligand 20%
• High Specificity 20%
• Monoclonal Antibody 20%
• SELEX 20%
• Adverse Reactions 20%
• Bone Mass 20%
• Osteoblast 20%
• Microarchitecture 20%
• Flatulence 20%
• Age-related Decline 20%
• Low Immunogenicity 20%
• Synthetic Oligonucleotides 20%
• Cellulitis 20%
• Bone Turnover 20%
• Eczema 20%
• Osteonecrosis of the Jaw 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Aptamer 100%
• Osteoclast Differentiation Factor 100%
• Denosumab 100%
• Oligonucleotide 33%
• Adverse Event 33%
• Receptor 33%
• Deterioration 16%
• Drug Delivery System 16%
• Nuclear Factor 16%
• Alternative Complement Pathway C3 C5 Convertase 16%
• Immunogenicity 16%
• Cellulitis 16%
• Human Monoclonal Antibody 16%
• Jaw Osteonecrosis 16%
• Flatulence 16%
• Eczema 16%

Immunology and Microbiology

• RANKL 100%
• Denosumab 100%
• Osteoclast 33%
• Drug Targeting 16%
• Complement Factor B 16%
• Osteolysis 16%
• RANK 16%
• Immunogenicity 16%
• Bone Turnover 16%
• Osteoblast 16%
• Bone Mass 16%
• Human Monoclonal Antibody 16%
• Jaw 16%
• Eczema 16%